Since the spring of 1952 we have undertaken a clinical trial of corticotropin in 21 cardiac patients with resistant edema. Of these, there were eight with arteriosclerotic, eight with chronic rheumatic, and three with hypertensive heart disease, while two had cor pulmonale. Beneficial results were obtained in 17, or 81 per cent of the cases. These consisted of a spontaneous diuresis either during corticotropin administration or after its withdrawal, or an alteration of response to mercurials, the patients subsequently responding favorably, whereas they had previously been completely refractory to the mercurial diuretics.
Since the spring of 1952, we have obtained sufficient clinical evidence and electrolyte balance data which promise to establish corticotropin (ACTH) as the therapeutic agent par excellence for the situation just described. This is the more fascinating if one recalls that to date corticotropin has been considered contraindicated in congestive heart failure due to its sodium-retaining effect. Well aware of its known physiologic actions at the time, we none- Presented at the Second World Congress of Cardiology, September [12] [13] [14] [15] [16] [17] 1954 , Washington, D. C. This work was supported (in part) by a research grant H-150-C, from the National Heart Institute, USPHS. This work was done during Dr. Cmara's tenure of a RItesearch Fellowship of the American Heart Association. 702 theless decided to start a clinical trial of corticotropin in the following categories of patients in whom there was little to lose: (1) those cardiac patients with truly resistant edema as described above, (2) heart patients with severe myocardial insufficiency (left ventricular) in whom there was severe pulmonary passive congestion and incapacitating, unrelievable paroxysms of dyspnea and (3) cardiac patients with severe, associated intrinsic bronchopulmonary disease (asthma, bronchiectasis, emphysema).
The initial trial of corticotropin in these cardiac patients was guided by the consideration that benefit might be obtained from the action of the hormone on some organ-system of the body which would offset that concerned with sodium retention through increased production of desoxycorticosterone-like substances by the adrenal cortices. This might possibly be in the form of improvement of the myocardium. With this thought, the clinical trial of corticotropin in heart disease was launched, but not without fear and trepidation. figure 3 shows that during and after the course of corticotropin, intranmuscular doses of Thiomerin were much more effective in prodlucing both water and sodium diuresis. The urine volumes were 6700 ml. and 7100 ml. Another patient, C. M., whose response to corticotropin was similar to that of the patient described above ( fig. 3, fig. 1) until the last day of corticotropin administration at which time he had already lost 13.1 Kg. of edema weight and had had sodium diuresis. There was no definite correlation betweell potassium administration and the start of natriuresis in the other patients studied in this series, hence it may be safely assumed that the small doses of potassium chloride administered did not play a major role ill inducing natriuresis.
In 1952 Andrus and his co-workers6 reported two patients with severe mitral stenosis in whom corticotropin therapy produced a striking improvement of respiratory function with clearing of pulmonary congestioll. The depression of respiratory function seen initially in those patients was of such severity as to render mitral valvuloplasty hazardous, but following improvement with corticotropii, they stood mitral valve surgery well, and were greatly benefited thereby. No comment was made on the effects of corticotropin on peripheral edema, although it was stated that the patients did gain weight in the course of corticotropin therapy. Their studies centered mainly on the effect of corticotropin on some of the pulmonary complications of mnitral stenosis, one of their main findings being a reduction of the abnormally high pulmonary artery pressure. No electrolyte studies were mentioned.
The mode of action by which corticotropin produces the salutary effects described in our report is worthy of speculation. Earle Furthermore, Earle and his co-workers point out that the rapidity with which changes occurred either on corticotropin administration or withdrawal suggest that the observed alterations in filtration rate and renal plasma flow were the result of functional (i.e., constriction of the efferent arterioles of the glomeruli, associated with dilatation of afferents) rather than morphological changes. Certainly then, the remissions observed in our patients, lasting in several instances as long as nine months, and in one instance 28 months, cannot be explained on the basis of temrnporarj changes in renal hemodynamics induced by corticotropin.
It may be mentioned in passing that Metcoff and co-workers,8 in a careful study of renal function in nephrotic children in whom diuresis was induced by corticotropin, came to the conclusion that altered renal hemlodynamics may be the result rather than the cause of favorable response.
Thus, the explanation for the beneficent effects of corticotropin in heart disease has to be sought along different lines. There is the possibility that corticotropin may stimulate the adrenocortical production of a hormone that has an action antagonistic to that of desoxycorticosterone, thus inducing diuresis niot only after, but even during the course of corticotropin therapy. An effect such as this has beeni reported with the use of cortisome in normal subjects9 and nephrotics. Luetscher 
